Opthea has completed enrollment of its phase 3 COAST and ShORe trials, which will investigate the safety and efficacy of sozinibercept in combination with anti-VEGF-A therapy for wet age-related macular degeneration.
According to a company press release, sozinibercept is a soluble form of VEGF receptor 3 that binds and neutralizes VEGF-C and VEGF-D on their endogenous receptors to prevent blood vessel growth and vascular leakage.
With a combined 1,984 treatment-naïve wet AMD patients, the two multicenter, double-masked, randomized trials comprise one the largest phase 3 programs in wet